Last reviewed · How we verify
KBMSI-2
KBMSI-2 is a Small molecule drug developed by Hyun Jun Park. It is currently FDA-approved. Also known as: Better man (brand name).
At a glance
| Generic name | KBMSI-2 |
|---|---|
| Also known as | Better man (brand name) |
| Sponsor | Hyun Jun Park |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KBMSI-2 CI brief — competitive landscape report
- KBMSI-2 updates RSS · CI watch RSS
- Hyun Jun Park portfolio CI
Frequently asked questions about KBMSI-2
What is KBMSI-2?
KBMSI-2 is a Small molecule drug developed by Hyun Jun Park.
Who makes KBMSI-2?
KBMSI-2 is developed and marketed by Hyun Jun Park (see full Hyun Jun Park pipeline at /company/hyun-jun-park).
Is KBMSI-2 also known as anything else?
KBMSI-2 is also known as Better man (brand name).
What development phase is KBMSI-2 in?
KBMSI-2 is FDA-approved (marketed).
Related
- Manufacturer: Hyun Jun Park — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Better man (brand name)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing